This study is the first time that K1-70 will be administered to humans. The principal aim of
this study is to obtain safety and tolerability data when K1-70 is administered as an IM
injection or as an IV infusion to subjects with Graves' disease.
Current therapy for Graves' disease includes treatment with anti-thyroid drugs, destruction
of the thyroid using radioiodine, or total surgical thyroidectomy. Beta-blockers and calcium
antagonists may be used to control some of the symptoms of hyperthyroidism.
K1-70 is a thyroid stimulating hormone receptor antagonist that may provide new in vivo
diagnostic and therapeutic tools for the management of patients with Graves' disease,
patients with thyroid cancer and patients who would benefit from controlling receptor
activity.